11.67
price down icon0.85%   -0.10
after-market After Hours: 11.67
loading
Zevra Therapeutics Inc stock is traded at $11.67, with a volume of 712.59K. It is down -0.85% in the last 24 hours and up +27.54% over the past month. Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
See More
Previous Close:
$11.77
Open:
$11.84
24h Volume:
712.59K
Relative Volume:
0.88
Market Cap:
$638.11M
Revenue:
$27.46M
Net Income/Loss:
$-46.05M
P/E Ratio:
-9.0465
EPS:
-1.29
Net Cash Flow:
$-33.83M
1W Performance:
-7.82%
1M Performance:
+27.54%
6M Performance:
+45.15%
1Y Performance:
+87.02%
1-Day Range:
Value
$11.52
$11.87
1-Week Range:
Value
$11.49
$12.80
52-Week Range:
Value
$5.45
$13.16

Zevra Therapeutics Inc Stock (ZVRA) Company Profile

Name
Name
Zevra Therapeutics Inc
Name
Phone
(321) 939-3416
Name
Address
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Name
Employee
59
Name
Twitter
Name
Next Earnings Date
2025-03-11
Name
Latest SEC Filings
Name
ZVRA's Discussions on Twitter

Compare ZVRA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ZVRA
Zevra Therapeutics Inc
11.67 633.19M 27.46M -46.05M -33.83M -1.29
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-02-25 Initiated H.C. Wainwright Buy
Jan-08-25 Resumed Cantor Fitzgerald Overweight
Oct-07-24 Initiated Guggenheim Buy
Sep-24-24 Initiated JMP Securities Mkt Outperform
Sep-24-24 Reiterated Maxim Group Buy
Apr-02-24 Reiterated Maxim Group Buy
Mar-12-24 Initiated William Blair Outperform
Mar-17-23 Initiated Maxim Group Buy
View All

Zevra Therapeutics Inc Stock (ZVRA) Latest News

pulisher
Jul 24, 2025

What analysts say about Zevra Therapeutics Inc. stockMarket-leading growth rates - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

Is Zevra Therapeutics Inc. a good long term investmentPhenomenal capital appreciation - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Zevra Therapeutics Inc. stock priceAccelerated capital growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

Zevra Therapeutics Inc. Stock Analysis and ForecastFree Investment Timing Strategies - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® - GlobeNewswire

Jul 18, 2025
pulisher
Jul 18, 2025

Zevra Therapeutics: Promising Growth Driven by Miplyffa Success and Strategic Focus on Rare Diseases - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

ZVRA Showcases Key Findings on MIPLYFFA and OLPRUVA at Genetics - GuruFocus

Jul 18, 2025
pulisher
Jul 18, 2025

Zevra Therapeutics Highlights Research on MIPLYFFA® and OLPRUVA® at 42nd Annual SERGG Meeting - Nasdaq

Jul 18, 2025
pulisher
Jul 17, 2025

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail

Jul 17, 2025
pulisher
Jul 17, 2025

William Blair Issues Optimistic Forecast for ZVRA Earnings - Defense World

Jul 17, 2025
pulisher
Jul 16, 2025

Zevra Therapeutics' MIPLYFFA: A Paradigm Shift in Rare Disease Treatment - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

5 Small Drug Stocks To Buy Amid Trump's New Tariff Threats - Barchart.com

Jul 16, 2025
pulisher
Jul 16, 2025

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

Zevra Therapeutics Publishes Long-Term Efficacy and Safety Results for MIPLYFFA in Niemann-Pick Disease Type C - Nasdaq

Jul 16, 2025
pulisher
Jul 16, 2025

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism - The Manila Times

Jul 16, 2025
pulisher
Jul 16, 2025

Breakthrough: New Clinical Data Shows MIPLYFFA Halts Rare Brain Disease Progression for 5 Years - Stock Titan

Jul 16, 2025
pulisher
Jul 16, 2025

Niemann-Pick Disease Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Treatment, Therapies and Companies by DelveInsight - The Globe and Mail

Jul 16, 2025
pulisher
Jul 15, 2025

ZVRA Publishes Positive Long-term Results for Arimoclomol in NPC Treatment | ZVRA Stock News - GuruFocus

Jul 15, 2025
pulisher
Jul 15, 2025

Why Zevra Therapeutics Inc. stock attracts strong analyst attentionEarly Buy Suggestion - newser.com

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Zevra Therapeutics Inc. stock price move sharplyHigh Yield Stock Selection - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Here's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA) - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

How Zevra Therapeutics Inc. stock performs during market volatilityBreakout Momentum Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of “Buy” from Analysts - Defense World

Jul 15, 2025
pulisher
Jul 14, 2025

Cantor Fitzgerald Issues Positive Outlook for ZVRA Earnings - Defense World

Jul 14, 2025
pulisher
Jul 12, 2025

Cantor Fitzgerald Forecasts Strong Price Appreciation for Zevra Therapeutics (NASDAQ:ZVRA) Stock - Defense World

Jul 12, 2025
pulisher
Jul 12, 2025

Zevra Therapeutics (NASDAQ:ZVRA) Upgraded to Strong-Buy at Wall Street Zen - Defense World

Jul 12, 2025
pulisher
Jul 12, 2025

Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) - GlobeNewswire

Jul 12, 2025
pulisher
Jul 11, 2025

Zevra(ZVRA) Soars 4.41% on Phase 2 Trial, Strategic Collaboration - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

ZVRA Highlights MIPLYFFA Data at Niemann Pick Conference | ZVRA Stock News - GuruFocus

Jul 11, 2025
pulisher
Jul 11, 2025

Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference | ZVRA Stock News - GuruFocus

Jul 11, 2025
pulisher
Jul 11, 2025

Zevra Therapeutics Showcases MIPLYFFA® Data at National Niemann Pick Disease Foundation Conference - Nasdaq

Jul 11, 2025
pulisher
Jul 11, 2025

Zevra Therapeutics presents MIPLYFFA data at NNPDF Conference, FDA-approved NPC treatment. - AInvest

Jul 11, 2025

Zevra Therapeutics Inc Stock (ZVRA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Cap:     |  Volume (24h):